27 completed, 12 active not recruiting, 7 terminated, 6 recruiting. 26 Phase 2, 20 Phase 3, 14 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow Peg-asparaginase: new trials by email Literature Review of Peg-asparaginase trials Research Report on Peg-asparaginase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-21 |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia Bortezomib - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 2 | Recruiting | Instituto do Cancer do Estado de São Paulo | 50 | 2024-04-01 | 2025-05-16 |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil Prednisone, Vincristin, Daunorubicin - Acute Lymphoid Leukemia, Minimal Residual Disease | Recruiting | Instituto do Cancer do Estado de São Paulo | 180 | 2023-09-05 | 2025-05-07 | |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Biospecimen Collection, Calaspargase Pegol, Levocarnitine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | Children's Oncology Group | 440 | 2023-08-24 | 2026-08-21 |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax Venetoclax, Navitoclax, Dexamethasone - Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 35 | 2022-08-25 | 2026-10-15 |
| Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2022-03-17 | 2026-05-28 |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 461 | 2020-12-17 | 2026-09-01 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Oncology Group | 5951 | 2019-10-31 | 2026-08-25 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-10-01 |
| Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 53 | 2019-04-03 | 2026-05-13 |
| Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL Pevonedistat, Vincristine, Dexamethasone - Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia | Phase 1 | Completed | Julio Barredo, MD | 6 | 2019-03-25 | 2022-10-20 |
| A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Daratumumab, Vincristine, Prednisone - Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | Completed | Janssen Research & Development, LLC | 47 | 2018-05-14 | 2025-05-25 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 2 | Active not recruiting | Children's Oncology Group | 80 | 2017-06-19 | 2026-10-01 |
| Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Azacitidine, Biospecimen Collection, Computed Tomography - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2017-04-01 | 2025-02-27 |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Prednisone, Vincristine, Daunorubicin - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma | Phase 2 / Phase 3 | Active not recruiting | St. Jude Children's Research Hospital | 790 | 2017-03-29 | 2026-06-17 |
| Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Dexamethasone, Panobinostat, Liposomal vincristine - Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2016-11-23 | 2019-04-03 |
| Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Rituximab, Nelarabine, PEG-Asparaginase - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 3 | Completed | Goethe University | 1023 | 2016-08-01 | 2025-12-16 |
Showing 20 of 56. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (37) · Burkitt Lymphoma (16) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (9) · Leukemia (8) · Leukemia, Biphenotypic, Acute (5) · Recurrence (5) · Lymphoma (4) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (4) · Down Syndrome (3) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell (2) · Neoplasms (2) · Hodgkin Disease (1) · Immunoproliferative Disorders (1) · Leukemia, B-Cell (1)
Children's Oncology Group (13) · National Cancer Institute (NCI) (12) · St. Jude Children's Research Hospital (6) · Dana-Farber Cancer Institute (3) · M.D. Anderson Cancer Center (3) · Therapeutic Advances in Childhood Leukemia Consortium (3) · Amgen (2) · Instituto do Cancer do Estado de São Paulo (2) · City of Hope Medical Center (1) · Emory University (1) · Goethe University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Janssen Research & Development, LLC (1) · Julio Barredo, MD (1) · Massachusetts General Hospital (1)
United States (49) · Canada (25) · Australia (23) · New Zealand (14) · Puerto Rico (12) · Switzerland (9) · Brazil (5) · Israel (5) · France (4) · Germany (4) · Italy (4) · Netherlands (4) · Sweden (4) · Austria (3) · Belgium (3)
Sima Jeha, MD (3) · Anne L Angiolillo (2) · Amir Fathi, MD (1) · Andrea Biondi (1) · Caroline A. Hastings, MD (1) · Damon Reed, M.D. (1) · Daniel DeAngelo, MD (1) · David T Teachey (1) · Eduardo M Rego, MD PhD (1) · Elias Jabbour (1) · Elizabeth Raetz, MD (1) · Eric C Larsen (1) · Etan Orgel (1) · Farhad Ravandi-Kashani (1)
PMID 37890117, PMID 39121442, PMID 41671463, PMID 26590194, PMID 29284596, PMID 35622074, PMID 36603187, PMID 38446568, PMID 40315406, PMID 42085640, PMID 12011123, PMID 20582937, PMID 21562038, PMID 22653976, PMID 23678006, PMID 24276047, PMID 24970932, PMID 26124497, PMID 26265699, PMID 27171984, PMID 29812996, PMID 30138085, PMID 30626253, PMID 30872105, PMID 31160295, PMID 32414848, PMID 32496902, PMID 32552472, PMID 32589970, PMID 32813610, PMID 33054114, PMID 33242441, PMID 33245179, PMID 33411585, PMID 33496745, PMID 33651090, PMID 33844429, PMID 34302711, PMID 35007127, PMID 35271306, PMID 36215217, PMID 37257143, PMID 37556734, PMID 38207208, PMID 38457359, PMID 38867582, PMID 39047240, PMID 39158071, PMID 39214018, PMID 39651791
U10CA180886 (15), U10CA098543 (12), 2014 (2), 2017 (2), 2005 (1), P30CA033572 (1), U01CA097452 (1), U10CA021115 (1), U10CA098413 (1), U10CA180820 (1), U10CA180888 (1), U10CA180899 (1), U24CA196172 (1), U24CA196173 (1), UG1CA189955 (1)